Anagliptin

Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Markets 2020-2021 & 2026: Focus on Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others - ResearchAndMarkets.com

Retrieved on: 
Monday, September 20, 2021
Health, Pharmaceutical, DPP-4, Linagliptin, Vildagliptin, Bristol-Myers Squibb Co. v. Superior Court, IDF, Merck & Co., GlaxoSmithKline, Diabetes, Novartis, Growth, Prevalence, E-64, International Diabetes Federation, Anagliptin, Pharmaceutical industry, Fine chemical

The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.

Key Points: 
  • The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.
  • However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs challenge the growth of the market.
  • The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type.
  • Geographically, the global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.